Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ondine Biomedical, Inc. (VF5) AI Stock Analysis

DE:VF5

Ondine Biomedical, Inc.

(Frankfurt:VF5)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthThe latest annual revenue increase indicates improving commercial traction and a growing base from which the company can develop its antimicrobial platform. If sustained, this expansion could provide greater operating scale and help support future investment in product development and commercialization.
Negative Factors
Severe Profitability WeaknessExtremely negative profitability and the sharp gross-margin decline show that revenue growth has not yet translated into a sustainable earnings model. Persistently weak margins can constrain reinvestment capacity, increase dependence on financing, and make future scaling less economically certain.

Ondine Biomedical, Inc. (VF5) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%60%DE:VF5-26.61%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 62.82M
Dividend Yield
―
Average Volume (3M)
1,000
Price to Earnings (P/E)
-2.8
Beta (1Y)
0.15
Revenue Growth
22.75%
EPS Growth
7.55%
Country
Germany
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Ondine Biomedical, Inc. Business Overview & Revenue Model

Company Description

Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Phot...

Ondine Biomedical, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:VF5 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:ONTGB:ONT59NeutralGBP 2.18B-17.72-27.36%―14.80%16.88%
GB:SBTXGB:SBTX59NeutralGBP 13.61M-29.17-5.25%―95.16%85.60%
GB:4BBGB:4BB52NeutralGBP 82.07M-4.57-316.73%―-56.10%-16.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:POLBGB:POLB46NeutralGBP 49.62M-8.33-71.28%――31.58%
GB:AVCTGB:AVCT43NeutralGBP 294.51M-6.63-1293.07%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:VF5GB:AVCTGB:SBTXGB:4BBGB:POLBGB:ONTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:VF5 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:VF5Ondine Biomedical, Inc.0.09-0.04-29.46%
GB:AVCTAvacta Group plc60.50-11.50-15.97%
GB:SBTXSkinBioTherapeutics plc5.25-10.88-67.44%
GB:4BB4basebio UK Societas530.00-255.00-32.48%
GB:POLBPoolbeg Pharma Ltd.6.502.6568.83%
GB:ONTOxford Nanopore Technologies PLC222.6087.1064.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.